The 20th Annual Meeting of Chinese Society of Clinical Oncology was held from September 27 to 30, 2017 in Xiamen. As one of the leading companies in the field of oncology drug development in China, Hansoh Pharma participated in the meeting in the form of “Hansoh Lung Cancer Satellite Meeting”, fully demonstrating the company's professional achievements and its brand image in the oncology field.
The "Hansoh Lung Cancer Satellite Meeting" attracted nearly 400 oncology specialists. It focused on the diagnosis and treatment of lung cancer for elder patients. The experts analyzed the unique characteristics and treatment strategies of elderly lung cancer patients, which enabled participants to have a clearer understanding of the treatment of elderly lung cancer. Subsequently, the participating experts conducted in-depth discussions on the diagnosis and treatment of clinical actual cases, and discussed in depth the many clinical hot spots and focus issues derived from the cases. At the conclusion of the meeting, the participating experts said that the setting of the topic of this meeting closely follows the clinical needs, which can lead to more useful thinking and exploration for clinicians in the treatment of non-small cell lung cancer.
During the meeting, Hansoh Pharma also showcased its corporate brand and product image by setting up a corporate image display area. Many experts and physicians who came to participate in the exhibition praised Hansoh Pharma's achievements in the field of oncology.
The annual CSCO meetings are the largest and most academically advanced event in the domestic oncology community. Under the theme of “Together we innovate on our inheritance”, this year’s meeting has attracted more than 30,000 oncologists and physicians from home and abroad. It has played an active role in further promoting academic exchanges and scientific and technological cooperation in the field of international and domestic clinical oncology, encouraging and supporting clinical research and innovation, advocating precision oncology on the basis of multidisciplinary and standardized comprehensive treatment, and facilitating the development of the discipline.
As a leading oncology drug R&D and manufacturing company, Hansoh Pharma’s products are widely used in various types of cancer treatment. For more than 20 years, Hansoh has been committed to the development of innovative drugs and market expansion with the mission of “Serving the society and building a healthy world”, providing clinicians with a variety of medication options. It has developed a number of high-quality oncology drugs such as Zefei (Gemcitabine Hydrochloride for Injection), Pulaile (Pemetrexed Disodium for Injection), Gainuo (Vinorelbine Tartrate for Injection), Xinwei (Imatinib Mesylate Tablets), Xinmei (Decitabine for Injection), etc. We will introduce international leading drugs and diagnosis and treatment programs to China through the professional promotion efforts of Hansoh Pharma’s staff throughout the country to allow patients to benefit from the most recent achievements in global pharmaceutical industry at an affordable cost. Hansoh is also actively deploying an internationalization strategy. It sells internationally certified oncology APIs and pharmaceutical products to Europe, the US and rest of the world. At the same time, it also commits itself to the research and development of innovative drugs both at home and abroad to contribute to the health cause of mankind.
